



ImpediMed Limited
1/50 Parker Court,
Pinkenba, QLD, 4008
Australia

E: investorrelations@impedimed.com

W: impedimed.com

9 April 2025

Companies Announcements Office
Australian Securities Exchange

ImpediMed anticipates no material impact from U.S. tariffs

ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company**) notes the recent announcement by the United States Administration to impose tariffs on imports to the U.S. After an initial assessment, the Company does not anticipate any material impact on its business or supply chain arising from these changes in the short to medium term.

Key points arising from this initial assessment include:

- The SOZO device is manufactured in the United States utilising third party manufacturers.
- A substantial number of components used in the SOZO device are manufactured in the U.S.
- ImpediMed is currently holding sufficient inventory of finished goods and components to shield its supply chain from near term external shocks.

Given the uncertain and evolving impact of the U.S. tariff policies on the global supply chain, the Company will continue to monitor these events and advise the market if there are any changes to this assessment.

Approved for release by the Chief Financial & Operating Officer of ImpediMed Limited.

For more information, contact Dr Parmjot Bains or McGregor Grant on +61 7 3860 3700.

About ImpediMed

Founded in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward Looking Statements

This announcement contains or may contain forward-looking statements that are based on ImpediMed management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed).